We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

15 hedge funds and large institutions have $369K invested in Plus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

67% more funds holding

Funds holding: 9 → 15 (+6)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.33% less ownership

Funds ownership: 0.46% → 0.13% (-0.33%)

53% less capital invested

Capital invested by funds: $780K → $369K (-$411K)

Holders
15
Holders Change
+6
Holders Change %
+66.67%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$114K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$90K
3
VF
Virtu Financial
New York
+$44.8K
4
UBS Group
UBS Group
Switzerland
+$37.4K
5
GSC
Ground Swell Capital
South Carolina
+$15.3K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$645K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.23K
3
TSS
Two Sigma Securities
New York
-$1.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
1
HRT Financial
New York
$96K +$114K +4,083 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$76.5K +$90K +3,220 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$54.2K -$1.23K -44 -2%
VF
4
Virtu Financial
New York
$38K +$44.8K +1,601 New
UBS Group
5
UBS Group
Switzerland
$31.8K +$37.4K +1,337 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$30.9K – – –
GSC
7
Ground Swell Capital
South Carolina
$13K +$15.3K +546 New
TSS
8
Two Sigma Securities
New York
$12.9K -$1.09K -39 -7%
TRCT
9
Tower Research Capital (TRC)
New York
$7.29K +$3.24K +116 +61%
BlackRock
10
BlackRock
New York
$6.61K – – –
Barclays
11
Barclays
United Kingdom
$987 +$1.17K +42 New
SS
12
SBI Securities
Japan
$245 +$196 +7 +233%
Citigroup
13
Citigroup
New York
$139 +$168 +6 New
Osaic Holdings
14
Osaic Holdings
Arizona
$126 – – –
Bank of America
15
Bank of America
North Carolina
$48 – – –
DB
16
Danske Bank
Denmark
$1 – – –
Group One Trading
17
Group One Trading
Illinois
$1 – – –
ACM
18
AIGH Capital Management
Maryland
– -$645K -22,436 Closed

PSTV Hedge Fund Activity: Q1 2025 in Review

15 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2025, worth a combined $369K — down 53% from $780K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PSTV positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $114K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $645K sold.

  • 15 institutional investors held Plus Therapeutics (PSTV) as of Q1 2025, up from 9 in Q4 2024.
  • Funds reported $369K of Plus Therapeutics stock for Q1 2025, down 53% quarter-over-quarter.
  • 7 funds opened new Plus Therapeutics positions in Q1 2025 and 1 closed out, a net change of +6 holders.
  • The largest Plus Therapeutics buyer in Q1 2025 was HRT Financial, an estimated $114K added.
  • The largest Plus Therapeutics seller in Q1 2025 was AIGH Capital Management, an estimated $645K sold.

Based on aggregated 13F filings for Q1 2025.